Recent advancements in acute myeloid leukemia (AML) treatment offer new hope, particularly for those with relapsed or refractory disease. Specifically,developments surrounding Revuforj® (revumenib) are noteworthy.
Syndax Pharmaceuticals recently announced that teh Food and Drug Administration (FDA) has granted priority review to its supplemental New Drug Submission (sNDA) for Revuforj. This application focuses on its use in patients with relapsed or refractory AML harboring an NPM1 mutation.
Here’s what you need to no about this advancement:
- Revuforj is a menin inhibitor designed to selectively target and degrade the NPM1-MLL fusion protein.
- This protein is a key driver of AML development in approximately 30% of AML patients.
- Priority review by the FDA typically means a faster assessment timeline, perhaps leading to quicker access for eligible patients.
I’ve found that understanding the specifics of these mutations is crucial for tailoring treatment plans. the FDA’s decision is anticipated by the end of 2024, and if approved, Revuforj coudl represent a notable step forward in addressing a challenging-to-treat form of AML.
You can find more facts about the sNDA submission and the ongoing research here.
Furthermore, details regarding the news release from Syndax Pharmaceuticals are available here.
Related reading